LONDON (dpa-AFX) - Healthcare company BTG plc (BTG.L) announced Wednesday that it is disappointed by a Memorandum Opinion issued by the Court of Chancery of Delaware ruling against BTG in its previously announced litigation with Wellstat Therapeutics Corp. The ruling is regarding the commercialisation of Vistogard.
The Court has found that BTG has breached the distribution agreement and that Wellstat is entitled to damages of $55.8 m plus interest and costs.
BTG said it is considering options, which include appealing the ruling and level of damages awarded.
Copyright RTT News/dpa-AFX